| Sheet | 1 | of | 1 |
|----------|---|----|---|
| α | | OI | ı |

| \0\F | |
|---------|--------------|
| JAH O 2 | Substitution |
| TRAD | PARTH CONT |

tute Form PTO-1449 ed)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 07064-009002

Application No. 09/940,235

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Rajesh Kumar, et al.

Applicant

Filing Date August 27, 2001 Group Art Unit 1652

(37 CFR §1.98(b))

| U.S. Patent Documents | | | | | | | | |
|-----------------------|--------------|--------------------|---------------------|----------|-------|----------|----------------------------|--|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate | |
| | AA | | | | | | | |
| | AB | | | | | | | |
| | AC . | | | | | | _ | |
| | AD | | | | | | | |
| | AE | | | | | | | |
| | AF | | | | | | | |

| | Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|----------|---|----------|-------------|---------------|-------|----------|-----|--------|--|
| Examiner | Desig. | Document | Publication | Country or | 01 | 0.1.1 | | lation | |
| Initial | ID | Number | Date | Patent Office | Class | Subclass | Yes | No | |
| | AG | | | | | | | | |
| | AH | | | | | | | | |
| | AI | | | | | | | | |
| | AJ | | | | | | | | |
| | AK | | | | | | | | |

| | Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | |
|----------|---|--|--|--|--|--|--|
| Examiner | Desig. | | | | | | |
| Initial | ID | Document | | | | | |
| 85 | AL | Pilar Alcala, et al., "Engineering of Escherichia coli β-galactosidase for solvent display of a Functional scFV Antibody Fragment," Federation of Europeam Biochemical Societies, pp 115-118 (2002). | | | | | |
| | AM | Sven-Olof Enfors, "Control of in vivo Proteolysis in the Production of Recombinant Proteins," <i>TibTech</i> , Vol. 10: pp 310-315 (1992). | | | | | |
| | AN | CF Ford, et al., 'Fusion Tails for the Recovery and Purification of Recombinar Proteins," <i>Protein Expr Purification</i> , pp. 95-107 (1991). | | | | | |
| | AO | Richard J. Jenny, et al., "A Critical Review of the Methods for Cleavage of Fusion Proteins with Thrombin and Factor Xa," <i>Protein Expression and Purification</i> , Vol. 31 pp. 1-11(2003). | | | | | |
| | AP | Shannon A. Marshall, et al. "Rational Design and Engineering of Therapeutic Proteins," Drug Discovery Today, Vol. 8, No. 5 pp. 212-221 (2003). | | | | | |
| 4 | AQ | Didier Picard, "Regulation of Protein Function Through Expression of Chimaeric Proteins," Current Opinion in Biotechnology, Vol: 5 p. 511-515 (1994). | | | | | |

| Examiner Signature | $\overline{}$ | | Date Considered | | |
|--|---------------|---|-----------------------------|-------|--------------------------------------|
| | N | Opel | | · ~ · | 04 |
| EXAMINER: Initials citation next communication to ap | | dered. Draw line through citation if no | t in conformance and not co | | |
| | | | | S | ubstitute Disclosure Form (PTO-1449) |